Navigation Links
Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
Date:4/15/2008

Companies Also Sign Manufacturing and Distribution Agreement

GURGAON, India and PRINCETON, N.J., April 15 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that it has reached several agreements with AstraZeneca. Two of these agreements concern Esomeprazole magnesium capsules. The third agreement pertains to Omeprazole 40mg tablets, and the fourth agreement pertains to Felodipine ER capsules. All of the agreements are specific to the U.S. market.

The agreement settles the patent infringement litigation filed by AstraZeneca following Ranbaxy's submission to the United States Food & Drug Administration of an Abbreviated New Drug Application for a generic version of Esomeprazole magnesium. Under the settlement agreement, Ranbaxy concedes that all six patents asserted by AstraZeneca in the patent litigation are valid and enforceable.

The settlement agreement will allow Ranbaxy to commence exclusive sales of a generic version of Nexium under a license from AstraZeneca on May 27, 2014. During the 180-day period following the date, RPI will distribute the only generic Esomeprazole magnesium product in the US market.

Ranbaxy has filed a Consent Judgment with the U.S. District Court for the District of New Jersey reflecting the terms of the settlement agreement. With the Court now having entered the Consent Judgment, the settlement agreement is final, and the patent infringement litigation against Ranbaxy has been dismissed.

Merck & Co., Inc., through KBI Inc. and KBI-E and under the terms of Merck's restructured partnership with AstraZeneca announced in 1998, has also entered into the settlement agreement.

"We are pleased with the agreement which will provide certainty as to the launch of a generic formulation of Esomeprazole magnesium in the US market," according to Malvinder M. Singh, CEO and Managing Director of Ranbaxy Laboratories Ltd.
'/>"/>

SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules
2. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
3. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
4. AstraZenecas Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016
5. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
6. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
8. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
9. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
10. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
11. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015  Novogen Limited (ASX:NRT; NASDAQ: ... advises that it has entered into definitive agreements ... shares plus one attaching 6-month option and half ... share issued, to institutional investors in ... placement for aggregate gross proceeds of approximately AU$15,500,000 ...
(Date:4/21/2015)... Springfield, Mo. (PRWEB) April 21, 2015 ... vessels, HOLLOWAY AMERICA is slated to discuss its custom ... also present its reimagined website, which launched just prior ... Wed. and Thurs. (April 21, 22 and 23) at ... than 12,000 representatives of the world’s largest and most ...
(Date:4/20/2015)... Winston-Salem, NC and Champaign, IL (PRWEB) April 20, 2015 ... announced today the establishment of its 12th clinical research ... 2015, PMG Research has assumed operation of the clinical ... IL, expanding PMG’s footprint outside the Southeast to a ... site within a 150 multi-specialty physician practice enhances PMG’s ...
(Date:4/20/2015)... -- "Everybody is affected by cancer sooner or later," Dr. ... We,ve got to get away from that."  If you,ve ... loved one or friend battling for their life against ... other treatments cause the human body. It,s almost enough ... succumb to the disease. Dr. Dionne has developed a ...
Breaking Biology Technology:Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 2Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 3Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 5Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 6HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 3PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 2PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 3Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2
... Sept. 19 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. ... CSKI ), a,leading fully integrated pharmaceutical company ... ("PRC"), announced today that it,has successfully completed the ... certification, or CE mark, which indicates that,a company,s ...
... seven medical,experts in psychiatry from across the world ... action to optimize services for people with a,diagnosis ... bipolar,disorder(i)., Professor W. Wolfgang Fleischhacker, principal author ... Disorders: Clinical,Policy, and Research Challenges which was published ...
... MedNet Solutions, a global,eClinical technology company specializing ... active involvement as a speaker,sponsor and exhibitor at ... Conference, to be held Sunday, September 21 through,Wednesday, ... has invited Dr. Timothy Pratt, PhD, Chief Marketing ...
Cached Biology Technology:China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification 2China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification 3Global Psychiatrists Unite to Improve Services in Mental Health 2Global Psychiatrists Unite to Improve Services in Mental Health 3MedNet Solutions to Speak, Sponsor and Exhibit at the 2008 Society of Clinical Data Management Annual Conference in Dallas 2
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/13/2015)... YORK , April 13, 2015 ... by TechSci Research, "Global Biometrics Market Forecast & Opportunities, ... register a CAGR of around 14% till 2020. ... governments for large scale implementation and review of ... and launch of new products with greater efficiency, ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... to double the odds a teenage girl will begin smoking, ... who analyzed the dieting and smoking practices of 8,000 adolescents, ... also less likely than girls to diet, according to findings ... Dieting was a significant predictor of initiation of regular smoking ...
... 2007- As of late, many uncertainties have been sprouting ... wondering if precision agricultural technologies can improve crop yield ... asking a number of questions from, which hybrid should ... applying nitrogen fertilizer at a uniform rate produce a ...
... Chicago researchers have identified new sites on the ... delivered to treat infections. "The primary challenge ... by the pathogens which became resistant to antibiotics," ... UIC,s Center for Pharmaceutical Biotechnology and lead investigator ...
Cached Biology News:Girls who begin dieting twice as likely to start smoking 2Girls who begin dieting twice as likely to start smoking 3The 5 Ws of corn production 2UIC researchers find promising new targets for antibiotics 2
... Blot Processing Standard Tray (3 per ... gel staining and blot processing.Automated staining ... for proteins and nucleic acid analysis.Prepares ... and chromogenic detection.Programmable control of protocol, ...
DITHIOTHREITOL, 150UMOL, 1 EA. Dithiothreitol (DTT), 0.1 M Solution:, *0.1 M solution of DTT in high purity dH2O., *0.2 m filtered., *Storage: -20C. Category: SEQUENASE....
GOAT ANTI HUMAN PARAINFLUENZA VIRUS 2+3...
75 x 25 mm; sterile, recommended for immunohistochemistry of cell lines growing in suspension, Poly-D-Lysine coated, glass slides with polystyrene vessel, lid and safety removal tool...
Biology Products: